UniProt Q13464 · PDB · AlphaFold · Substrate: Long S6 Kinase substrate peptide · Clone: aa 1-535
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Netarsudil | 99.3% | 0.7% | 93.22 | 0.676 |
| 2 | Capivasertib | 88.4% | 11.6% | 96.48 | 0.644 |
| 3 | Baricitinib | 81.7% | 18.3% | 97.99 | 0.616 |
| 4 | Ruxolitinib | 63.6% | 36.4% | 98.25 | 0.592 |
| 5 | Upadacitinib | 47.4% | 52.6% | 97.98 | 0.663 |
| 6 | Gilteritinib | 42.3% | 57.7% | 88.97 | 0.506 |
| 7 | Abemaciclib | 41.9% | 58.1% | 91.48 | 0.563 |
| 8 | Repotrectinib | 38.0% | 62.0% | 84.21 | 0.608 |
| 9 | Abrocitinib | 29.4% | 70.6% | 99.50 | 0.581 |
| 10 | Darovasertib | 25.0% | 75.0% | 96.99 | 0.719 |
| 11 | Brigatinib | 24.6% | 75.4% | 82.96 | 0.513 |
| 12 | Ceritinib | 22.0% | 78.0% | 95.44 | 0.618 |
| 13 | Midostaurin | 21.7% | 78.3% | 78.64 | 0.500 |
| 14 | Ponatinib | 21.3% | 78.7% | 78.23 | 0.534 |
| 15 | Bosutinib | 17.7% | 82.3% | 87.22 | 0.555 |
| 16 | Lorlatinib | 16.8% | 83.2% | 97.24 | 0.694 |
| 17 | Canertinib | 16.6% | 83.4% | 96.49 | 0.671 |
| 18 | Sunitinib | 13.4% | 86.6% | 91.73 | 0.524 |
| 19 | Remibrutinib | 13.1% | 86.9% | 99.50 | 0.721 |
| 20 | Defactinib | 12.6% | 87.4% | 92.68 | 0.450 |
Paralog block
ROCK1, ROCK2
EMT expression
- Mesenchymal log2(TPM+1): 4.48
- Epithelial log2(TPM+1): 3.86
- Fold change: 0.62
- Status: No significant change
Selectivity landscape vs inhibition on ROCK1
Each point is one of the 92 approved drugs; color = inhibition % on ROCK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…